Stem cell co. faked success: SEC

September 10, 2009

A stem cell company is in hot water with the US Securities and Exchange Commission (SEC) for falsely representing an early-stage experimental stem cell therapy as nearing human trials. The SEC yesterday (September 8) filed charges against CellCyte, based in Bothell, Wash., as well as the company’s former CEO and former chief scientific officer who were involved in the alleged deception, according to Forbes.com. (The Scientist)